Klerwipe Low Residue Quat

المعلومات الرئيسية

  • اسم تجاري:
  • Klerwipe Low Residue Quat
  • يسخدم من اجل:
  • البشر
  • نوع الدواء:
  • الجهاز الطبي

المستندات

  • لعامة الناس:
  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.


    طلب نشرة المعلومات لعامة الناس.

الأقلمة

  • متاح في:
  • Klerwipe Low Residue Quat
    كازاخستان
  • اللغة:
  • العربية

معلومات أخرى

الحالة

  • المصدر:
  • Ecolab
  • تخويل:
  • 912875-03
  • اخر تحديث:
  • 12-03-2018

ملخص خصائص المنتج

Klerwipe Low Residue Quat

912875-03

1 / 6

Klerwipe Low Residue Quat

00971 4 8014444

00971 48146800 00971 4 8014000

0020 2 25 37 1195

00212 22 58 25 30 - 35

00971 4 8014444 :

00971 48146800 00971 4 8014000

0020 2 25 37 1195 :

00212 22 58 25 30 - 35 :

15.09.2017

GHS

:

:

:

Klerwipe Low Residue Quat

912875-03

2 / 6

Klerwipe Low Residue Quat

912875-03

3 / 6

0 °C

25 °C

5.5 - 7.5

100 %

0.995 - 1.005

Klerwipe Low Residue Quat

912875-03

4 / 6

Klerwipe Low Residue Quat

912875-03

5 / 6

(ADR/ADN/RID)

Klerwipe Low Residue Quat

912875-03

6 / 6

)

(

)

IMDG/

(

15.09.2017

Regulatory Affairs

  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.

    طلب نشرة المعلومات لعامة الناس.



  • وثائق في اللغات الأخرى المتاحة هنا

10-7-2018

Federal judge enters consent decree against Minnesota dairy farm for drug residue violations

Federal judge enters consent decree against Minnesota dairy farm for drug residue violations

Federal judge enters consent decree against Minnesota dairy farm for drug residue violations

FDA - U.S. Food and Drug Administration

10-7-2018

FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions

FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions

FDA is requiring safety labeling changes for fluoroquinolones to strengthen the warnings about the risks of mental health side effects and serious blood sugar disturbances.

FDA - U.S. Food and Drug Administration

10-7-2018

Fluoroquinolone Antibiotics: FDA Requires Labeling Changes Due to Low Blood Sugar Levels and Mental Health Side Effects

Fluoroquinolone Antibiotics: FDA Requires Labeling Changes Due to Low Blood Sugar Levels and Mental Health Side Effects

FDA is strengthening the current warnings in the prescribing information that fluoroquinolone antibiotics may cause significant decreases in blood sugar and certain mental health side effects.

FDA - U.S. Food and Drug Administration

26-6-2018

Huish Outdoors recalls Oceanic and Hollis Scuba Diving Regulators

Huish Outdoors recalls Oceanic and Hollis Scuba Diving Regulators

The scuba diving regulators can restrict airflow at low tank pressures (below 500 psi), posing a drowning hazard to divers.

Health Canada

4-6-2018

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System   by Hospira: Recall - Due to the Potential Presence of Particulate Matter

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System by Hospira: Recall - Due to the Potential Presence of Particulate Matter

The patient has a low likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity.

FDA - U.S. Food and Drug Administration

31-5-2018

Abbott Implements Corrective Action for Heartmate 3 Heart Pump

Abbott Implements Corrective Action for Heartmate 3 Heart Pump

Abbott is communicating to physicians about a field corrective action related to the HeartMate 3™ Left Ventricular Assist Device (LVAD). Abbott notified physicians and global regulatory bodies on April 5, 2018, that outflow graft twisting could occur post-implant in the HeartMate 3 LVAD, resulting in a persistent low flow alarm that may signal a potential safety risk to patients, such as low blood flow or clotting.

FDA - U.S. Food and Drug Administration

29-5-2018

Under Armour Inc. recalls Yard Low DT and Highland Yard DT Cleats

Under Armour Inc. recalls Yard Low DT and Highland Yard DT Cleats

The Yard DT cleats are prone to splitting and/or breaking apart. If the Yard DT cleat were to crack or otherwise break while the user is trying to change directions while running, the user could sustain an injury.

Health Canada

22-5-2018

HeartMate 3™ Left Ventricular Assist System: Class I Recall - Due to Potential Malfunction that may Lead to Graft Occlusion

HeartMate 3™ Left Ventricular Assist System: Class I Recall - Due to Potential Malfunction that may Lead to Graft Occlusion

The class I recall is due to a malfunction in the device’s outflow graft assembly that may cause the outflow graft to twist and close up (occlusion) over time. Occlusion of the outflow graft can reduce or stop pump flow and set off a persistent low flow alarm in the system. A reduction in pump can lead to serious adverse events such as blood clots and death.

FDA - U.S. Food and Drug Administration

21-5-2018

FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure

FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure

FDA approves Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical procedure.

FDA - U.S. Food and Drug Administration

18-5-2018

Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy

Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy

Early reviews found patients in the monotherapy arms of both trials with PD-L1 low status had decreased survival compared to patients who received cisplatin- or carboplatin-based chemotherapy.

FDA - U.S. Food and Drug Administration

5-3-2014

Danish Pharmacovigilance Update 31 October 2013

Danish Pharmacovigilance Update 31 October 2013

In this issue of Danish Pharmacovigilance Update: The risk of blood clots from the use of contraceptive pills is low regardless of type, Report of cardiac arrest in association with the use of flecainide (Tambocor®).

Danish Medicines Agency

22-2-2012

Decision on general conditional reimbursement for alendronate-containing medicines

Decision on general conditional reimbursement for alendronate-containing medicines

In cooperation with the Reimbursement Committee, we have decided to grant alendronate-containing medicines general conditional reimbursement from 5 March 2012. Reimbursement is conditional as it is reserved for patients with low-energy hip fractures. For any other patients who are treated with alendronate, the doctor must apply for single reimbursement, and the guiding criteria for single reimbursement remain unchanged for these patients. Alendronate is used for the treatment of osteoporosis (brittle bon...

Danish Medicines Agency

1-7-2018

Annual Charge Exemption (ACE) scheme forms

Annual Charge Exemption (ACE) scheme forms

A declaration of low value ($0) turnover can be made between 1 and 22 July

Therapeutic Goods Administration - Australia

21-6-2018

Submissions received: Options for the future regulation of 'low risk' products

Submissions received: Options for the future regulation of 'low risk' products

All submissions that gave permission to be published on the TGA website are now available

Therapeutic Goods Administration - Australia

21-6-2018

The future regulation of low risk products

The future regulation of low risk products

The TGA response to the future regulation of low risk products has been released

Therapeutic Goods Administration - Australia

7-6-2018

News and press releases:  Changes to submission and assessment of maximum residue limits of veterinary medicines in foods

News and press releases: Changes to submission and assessment of maximum residue limits of veterinary medicines in foods

Three new implementing regulations replace current guidance

Europe - EMA - European Medicines Agency

1-6-2018

News and press releases:  EMA restricts use of Keytruda and Tecentriq in bladder cancer

News and press releases: EMA restricts use of Keytruda and Tecentriq in bladder cancer

Data show lower survival in some patients with low levels of cancer protein PD-L1

Europe - EMA - European Medicines Agency